Sirius XM Holdings Inc vs 10X Genomics Inc — how do they compare? Sirius XM Holdings Inc trades at $28.29 (market cap $9.70B), while 10X Genomics Inc trades at $57.22 (market cap $7.61B). The key difference: Sirius XM Holdings Inc is the larger of the two by market cap, and Sirius XM Holdings Inc pays a 3.75% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| SIRI | TXG | |
|---|---|---|
Market Cap | $9.70B | $7.61B |
Sector | Media | Health |
52-Week High | $32.59 | $58.57 |
52-Week Low | $19.92 | $11.34 |
Enterprise Value | $18.98B | $7.14B |
Dividend Yield | 3.75% | — |
Signals from Pluang's Aura AI — not financial advice
Sirius XM Holdings (SIRI) trades at $28.275, down 1.75% today, with a bearish technical signal and mixed earnings history including a Q2 2026 miss. The company maintains stable cash flow, with Q2 revenue up 1% year-over-year and raised 2026 guidance. Valuation appears attractive with a P/E of 11.56 and P/B below 1, while a $0.27 dividend provides income support.
Outlook: SIRI offers value with solid fundamentals and shareholder returns, but faces competitive pressures and subscriber volatility. Risks include high debt and market sentiment shifts. Analysts see 17% upside to the $33.17 consensus target, supporting a cautious buy view for income-focused investors.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Trailing returns across standard periods
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →